Skip to content
Regen Biopharmainc

Menu

Regen Biopharmainc

Menu

Category: Uncategorized

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled “Dual…

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today initiation of a series of phased experiments to begin the process of…

Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors…

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a…

Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), announced today the filing with the United States Patent and Trademark Office of a…

Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has an extensive intellectual property portfolio consisting of granted patents, published…

Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The…

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology

Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine…

REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP): First of all I would like to wish all our shareholders a happy holiday season. It has been a…

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine

Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP) is currently completing a strategic analysis of its next 5 years of growth. As part of this…

← Previous
Next →
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA.
  • Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • Investor Relations
  • News
  • Careers
  • Contact Us
Back to top

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Terms Of Use
  • Accessibility
Twitter
  • Founded in 2012 as a biotechnology company focused on immunotherapy and autoimmunity.
  • Fully reporting and trading under the symbols RGBP and RGBPP.
  • Currently focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers .
  • 1 IND cleared and 2 INDs submitted with the FDA. Diverse pre-clinical pipeline including platform technologies .
  • Strong intellectual property protected by multiple patents
  • Terms Of Use
  • Accessibility

Quick Links

  • Home
  • About Us
  • Product Pipeline
  • News
  • Management Team
  • Investor Relations​
  • Contact Us
Back to top
  • Terms Of Use
  • Accessibility
Twitter

© COPYRIGHT 2023. ALL RIGHTS RESERVED.

  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Inverstor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
  • Home
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates

An overview of Regen BioPharma

  • About Us​
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us

Our management, scientific advisory board and intellectual property

  • Product Pipeline
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC
  • DuraCAR
  • KimerApt
  • HemaXellerate
  • dCellVax
  • tCellVax
  • DiffronC

Details around our intellectual property and its development

  • Investor Relations
  • Regulatory Filings
  • Regulatory Filings

Our public filing and stock information

  • Company News
  • Featured News
  • News and Updates
  • Featured News
  • News and Updates

Our press releases and upcoming events

  • Home

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • About Us​

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Products

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Investor Relations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • Company News

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • What we do
  • Product Pipeline
  • Investor Relations
  • News & Updates
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Management Team and Scientific Advisory Board
  • Careers 
  • Contact Us
  • Regulatory Filings
  • Regulatory Filings
  • Contact us
  • Careers
  • Press Releases
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases
Twitter
Home

What we do

Product Pipeline

Inverstor Relations

News & Updates

About Us

Management Team and Scientific Advisory Board

Careers

Contact Us

Product Pipeline

DuraCAR

KimerApt

HemaXellerate

dCellVax

tCellVax

DiffronC

Investor Relations

Regulatory Filings

Company News

Featured News

News and Updates

  • Contact us
  • Careers
  • Press Releases
Twitter
  • Contact us
  • Careers
  • Legal notice
  • Cookies policy
  • Privacy policy
  • Partnership
  • Covid-19
  • Press Releases